TSX:HLS • CA40390B1094
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for HLS THERAPEUTICS INC (HLS.CA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-11-11 | Stifel Nicolaus Research | Downgrade | |
| 2022-10-26 | Stifel Nicolaus Research | Maintains | Buy |
| 2022-08-25 | Raymond James Capital | Downgrade | Outperform |
| 2022-08-12 | Stifel Nicolaus Research | Downgrade | |
| 2022-05-06 | Raymond James Capital | Initiate | Outperform |
| 2022-04-27 | Clarus Securities | Reiterate | Buy |
| 2022-04-27 | Raymond James Capital | Upgrade | Outperform |
| 2022-03-21 | Clarus | Initiate | Buy |
| 2022-03-20 | Raymond James Capital | Initiate | Outperform |
| 2022-03-20 | Canaccord Capital | Downgrade | Buy |
| 2022-03-15 | Raymond James Capital | Initiate | Outperform |
| 2022-03-10 | Stifel Nicolaus Research | Initiate | Buy |
| 2021-12-16 | Raymond James Financial | Initiate | Outperform |
| 2021-11-05 | RJ Financial | Initiate | Outperform |
| 2021-10-28 | Raymond James Financial | Initiate | Outperform |
| 2021-08-17 | Raymond James Financial | Upgrade | Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 63.074M 2.56% | 56.619M -10.23% | 55.5M -1.98% | 58.58M 5.55% | 65.499M 11.81% | 70.094M 7.02% | 80.901M 15.42% | 89.789M 10.99% | 97.869M 9.00% | |
| EBITDA YoY % growth | 20.129M -3.69% | 13.523M -32.82% | 16.333M 20.78% | 20.503M 25.53% | 24.341M 18.72% | 30.3M 24.48% | 35.653M 17.67% | 39.491M 10.76% | 45.046M 14.07% | |
| EBIT YoY % growth | -11.81M 12.52% | -9.194M 22.15% | -5.484M 40.35% | -4.646M 15.28% | 1.212M 126.09% | 6.06M 400.00% | 11.413M 88.33% | 15.251M 33.63% | 20.806M 36.42% | |
| Operating Margin | -18.72% | -16.24% | -9.88% | -7.93% | 1.85% | 8.65% | 14.11% | 16.99% | 21.26% | |
| EPS YoY % growth | -0.85 -44.07% | -0.62 27.06% | -0.39 37.10% | -0.36 6.77% | -0.11 69.44% | 0.03 127.27% | 0.18 500.00% | 0.29 61.11% | 0.44 51.72% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.12 13.43% | -0.11 -17.83% | -0.08 32.67% | -0.06 -51.50% | -0.05 58.33% | -0.03 71.43% | -0.03 62.50% | 0.00 100.00% |
| Revenue Q2Q % growth | 13.332M 5.62% | 14.797M 4.42% | 14.544M 7.65% | 15.958M 5.02% | 13.837M 3.79% | 15.756M 6.48% | 15.756M 8.33% | 17.473M 9.49% |
| EBITDA Q2Q % growth | 4.04M 40.62% | 4.646M -53.70% | 5.202M -63.99% | 5.858M -72.80% | 5.555M 37.50% | 6.262M 34.78% | 6.464M 24.26% | 7.171M 22.41% |
| EBIT Q2Q % growth | -2.525M -1.53% | -1.414M -74.78% | -808K 57.65% | 202K 172.14% | -505K 80.00% | 202K 114.29% | 404K 150.00% | 1.111M 450.00% |
All data in USD
8 analysts have analysed HLS.CA and the average price target is 8.27 CAD. This implies a price increase of 80.28% is expected in the next year compared to the current price of 4.59.
HLS THERAPEUTICS INC (HLS.CA) will report earnings on 2026-05-07.
The consensus EPS estimate for the next earnings of HLS THERAPEUTICS INC (HLS.CA) is -0.12 CAD and the consensus revenue estimate is 13.33M CAD.
The consensus rating for HLS THERAPEUTICS INC (HLS.CA) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.